27th Jul 2006 07:01
Stem Cell Sciences plc27 July 2006 27.7.06 Immediate Release (Stem Cell Sciences plc. AIM: STEM) NON-EXECUTIVE DIRECTOR APPOINTMENT Stem Cell Sciences plc (AIM:STEM) is pleased to announce thatJeremy Paul Scudamore, aged 59, has been appointed to the Stem Cell SciencesBoard of Directors as Non-executive Director with immediate effect. Jeremy Scudamore was educated at Nottingham University. He joined I.C.I. as anEconomist and worked for the I.C.I. Group and later Zeneca in a number ofinternational commercial and strategic management roles. He has considerableexperience of Business in the Americas, Europe, Africa the Middle East and Asia.He became Business Director for Zeneca Agrochemicals, Managing Director ofZeneca Seeds and Plant science and then Chief Executive Officer of ZenecaSpecialties. In 1998/9 he led the £1.3bn buyout of Zeneca Specialties fromAstraZeneca to form the Avecia Group. At the time, this was the largest everbuyout in Europe. He was appointed CEO and later Chairman of the Avecia Group.Having restructured and successfully divested all but the Biotechnologybusinesses, he retired in 2006. Jeremy has been Chair of the UK Chemicals Innovation team for the DTI, was onthe Boards of the Chemical Industry Association, Chemical and Engineering News(Washington USA), European Chemical News, and was Chairman of Cyprotex plc. Jeremy is currently a Non -executive Director of ARM Holdings plc and Chair ofthe North West Science Council. Peter Mountford, CEO of Stem Cell Sciences commented; "Jeremy has extensiveexpertise in growing global businesses and maximising shareholder value. He isa valuable addition to our Board. We are thrilled to have him on the team andlook forward to working with him." Current Appointments Held: Company Name Position AppointedARM HOLDINGS PLC Director 26/04/2004 Past Appointments Held: Company Name Position Appointed ResignedADVANTA RESEARCH LIMITED Director 06/02/1995 15/05/1998ADVANTA TECHNOLOGY LIMITED Director 01/12/1995 15/05/1998AVECIA BIOTECH PROPERTIES LIMITED Director 30/03/2005 04/10/2005AVECIA FINE CHEMICALS LIMITED Director 18/02/2005 16/09/2005AVECIA FINANCE PLC Director 23/06/1999 22/03/2006AVECIA GROUP PLC Director 23/06/1999 22/03/2006AVECIA HOLDINGS PLC Director 23/06/1999 22/03/2006AVECIA 10 LIMITED Director 23/06/1999 17/03/2006AVECIA CORPORATION LIMITED Director 23/06/1999 22/03/2006AVECIA LIMITED Director 23/06/1999 22/03/2006AVECIA PHARMACEUTICALS LIMITED Director 21/02/2005 02/12/2005AVECIA INKJET LIMITED Director 18/02/2005 17/02/2006AVECIA INVESTMENTS LIMITED Director 13/07/1999 22/03/2006AVECIA TRADING LIMITED Director 23/06/1999 31/07/2003AVECIA TONER RESINS LIMITED Director 23/06/1999 04/10/2005AVECIA UK HOLDINGS LIMITED Director 23/06/1999 22/03/2006AV NO. 2 LIMITED Director 22/01/2002 22/03/2006AV NO.3 LIMITED Director 23/06/1999 19/04/2004CHEMICAL INDUSTRIES ASSOCIATION LIMITED Director 20/05/2000 03/01/2006CYPROTEX SERVICES LIMITED Director 04/12/2001 17/02/2003ICI(NOMINEE HOLDINGS) LIMITED Director 06/09/1992 04/01/1994ILIAD 3 LIMITED Director 23/06/1999 30/03/2004ZENECA INTERNATIONAL LIMITED Director 15/09/1993 01/07/1997 - Ends - For further information, please contact: Stem Cell Sciences plcPeter Mountford, Chief Executive Officer 0131 662 9829 Weber Shandwick Square Mile 020 7067 0700James Chandler/James White Notes to EditorsStem Cell Sciences plc (SCS, AIM: STEM) is a global biotechnology companyproviding products in the burgeoning stem cell research and drug discoverymarkets, in addition to the targeted development of cell-based therapies forneurodegenerative disease and injury. The Company has established a leading intellectual property (IP) and technologyportfolio that enables the commercial application of stem cells in drugdiscovery, providing the Company with early-stage revenue streams and technologydevelopment for at scale cell production of SCS cell-based therapeutics. SCS principal focus is in neurological disease. Revenues in the neurotechmarket, including pharmaceuticals, devices and diagnostics, grew 10% in 2005 toUS$110 billion*. SCS operates as a group of independent operations with laboratories in Scotland,Japan and Australia, each of which is affiliated with an academic centre ofexcellence. These include the Institute of Stem Cell Research (ISCR), Edinburgh,UK, RIKEN Centre for Development Biology, Kobe, Japan and the Australian StemCell Centre, Melbourne, Australia. SCS has four business units focused on key sustainable business strategies. SC Proven(TM)provides cell culture media (liquid formulations) and reagents thatenable the growth and differentiation of stem cells. The first commerciallyavailable product, a novel, serum free, stem cell growth medium, has beenexclusively licensed for manufacture and marketing to Chemicon, a division ofSerologicals Inc. SC Licensing licenses SCS proprietary technologies, such as Internal RibosomeEntry Site (IRES) and Stem Cell Selection, for application in laboratory-basedresearch and discovery. SCS has licensed technology to major pharmaceutical andbiotechnology companies including Pfizer, Sanofi Aventis, GSK, Deltagen Inc andLexicon Genetics Inc. SC Services provides specialised stem cell production for basic research anddrug discovery, including high-throughput applications. SC Therapies goal is to develop safe and effective cell-based therapies forcurrently incurable diseases. SCS is conducting preclinical evaluations of itsneural stem cell lines in a number of therapeutic applications. The firstpreclinical programme is being undertaken by SCS' Japanese affiliate, whichrecently announced the exclusive licensing of human multi-potent adipose-derivedstem (hMADS) cells for therapeutic purposes. SCS KK will conduct preclinicalstudies for the treatment of Duchene's Muscular Dystrophy in 2006. This information is provided by RNS The company news service from the London Stock ExchangeRelated Shares:
SThree